Drug Search Results
More Filters [+]

colistin

Alternative Names: colistin
Latest Update: 2024-10-29
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: N/A

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous,Inhalant

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Bosnia | Bulgaria | Canada | Chile | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | South Africa | Sweden | Switzerland | Taiwan | Tunisia | Ukraine | United Arab Emirates | United Kingdom | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: AZIENDA OSPEDALIERA MEYER
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for colistin

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Urinary Tract Infections

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2019-000910-12

P2

Active, not recruiting

Urinary Tract Infections

2021-02-08

Recent News Events